121507-34-4

Basic information

• Product Name: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI)
• Synonyms: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI);5-(propan-2-yloxy)-1H-pyrazol-3-aMine;1H-Pyrazol-3-aMine, 5-(1-Methylethoxy)-
• CAS NO: 121507-34-4
• Molecular Formula: C₆H₁₁N₃O
• Molecular Weight: 141.17104
• Product Categories: VARIOUSAMINE
• Mol File: 121507-34-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI)(121507-34-4)
• EPA Substance Registry System: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI)(121507-34-4)

Safety Data

• Hazardous Substances Data: 121507-34-4(Hazardous Substances Data)

Usage

Uses

5-Isopropoxy-1H-pyrazol-3-amine pois involved with the synthesis and biol. evaluation of 2-(α-arylalkylamino)-4-(pyrazolylamino)pyrimidines as potent inhibitors of Trk kinases.

Upstream product

• 140-87-4 Cyanoacetohydrazide 
• 67-63-0 isopropyl alcohol 
• 53666-79-8 5-amino-2H-pyrazol-3-ol 

Downstream Products

• 1079274-94-4 (S)-N-(1-(5-fluoropyrimidin-2-yl)ethyl)-3-(5-isopropoxy-1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-5-amine 
• 1269515-15-2 2,6-difluoro-N-(2-isopropoxypyrazolo[1,5-a]pyrimidin-6-yl)-3-(propylsulfonamido)benzamide 
• 1192233-23-0 N-(5-isopropoxy-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-3-yl)-3-(pyridin-2-ylsulfonyl)benzamide 
• 1192232-58-8 N-(3-isopropoxy-1H-pyrazol-5-yl)-3-(pyridin-2-ylsulfonyl)benzamide 
• 868596-01-4 N-(5-fluoro-2-nitrophenyl)-5-isopropoxy-1H-pyrazol-3-amine 

Relevant articles and documents

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases

The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4- aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of 10z (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.

5-AMINOPYRAZOL-3-YL-3H-IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.